Our results also suggested that a CDK inhibitor would be useful in the treatment of ESCC by enhancing the sensitivity to chemotherapy especially in patients with PFTK1(+) tumours, in support of previous reports (Schwartz et al, 2002). The gene discussed is CDK14; the disease is neoplasm.